The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Considerations and caveats in anti-virulence drug development
Open accessAbstract
As antibiotic resistance remains a major public health threat, anti-virulence therapy research is gaining interest. Hundreds of potential anti-virulence compounds have been examined, but very few have made it to clinical trials and none have been approved. This review surveys the current anti-virulence research field with a focus on the highly resistant and deadly ESKAPE pathogens, especially Pseudomonas aeruginosa. We discuss timely considerations and caveats in anti-virulence drug development, including target identification, administration, preclinical development, and metrics for success in clinical trials. Development of a defined pipeline for anti-virulence agents, which differs in important ways from conventional antibiotics, is imperative for the future success of these critically needed drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence
Liu, C.-I., Liu, G. Y., Song, Y., Yin, F., Hensler, M. E., Jeng, W.-Y., Nizet, V., Wang, A. H.-J., & Oldfield, E. (2008) · Science · doi:10.1126/science.1153018 · Cited by 490
Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment
Ross-Gillespie, A., Weigert, M., Brown, S. P., & Kümmerli, R. (2014) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eou003 · Cited by 104
Cited by
Nanoparticle-based local antimicrobial drug delivery
Gao, W., Chen, Y., Zhang, Y., Zhang, Q., & Zhang, L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.015 · Cited by 396
Fleitas Martínez, O., Cardoso, M. H., Ribeiro, S. M., & Franco, O. L. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00074 · Cited by 304
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Metadata
- Authors
- Maura, D., Ballok, A. E., & Rahme, L. G.
- Venue
- Current Opinion in Microbiology
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 33
- Pages
- 41-46
- ISSN
- 1369-5274 (ISSN-L)
- OpenAlex
- W2439096783
- Cited by
- 159
- References
- 4
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Considerations and caveats in anti-virulence drug development. https://app.cochat.ai/papers/10.1016/j.mib.2016.06.001
- The paper
- Maura, D., Ballok, A. E., & Rahme, L. G. (2016). Considerations and caveats in anti-virulence drug development. Current Opinion in Microbiology. https://doi.org/10.1016/j.mib.2016.06.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
